Demand for Cannabinol (CBN) Could Create a Massive Opportunity

At the moment, CBN, or cannabinol is soaring in popularity. That could be significant news for companies, like Xebra Brands (CSE: XBRA) (OTCQB: XBRAF), which is launching one of the only beverages in Canada with CBN, Vicious Citrus. According to, “Studies have shown that THC works synergistically with other cannabinoids to enhance the overall effect when consumed together. CBN is a cannabinoid that both consumers and researchers have expressed growing excitement about for its adult-use effects and potential medicinal benefits.” Other cannabis companies benefiting from the cannabis beverage boom include Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), Canopy Growth (TSX: WEED) (NASDAQ: CGC), Tilray Inc. (NASDAQ: TLRY) (TSX: TLRY), and OrganiGram Holdings (NASDAQ: OGI) (TSX: OGI).

In addition, according to Grand View Research, the market could be worth $2.8 billion by 2025. “The rising popularity of wellness drinks is also expected to support the demand over the forecast period. The legalization of cannabis for medical and recreational purposes has had a strong impact on the sales of alcoholic drinks. As a result, many alcohol manufacturers are investing in the growing trend of marijuana-infused drinks,” they noted.

Xebra Brands’ (CSE: XBRA) (OTCQB: XBRAF) THC and CBN Cannabis Infused Lemonade Accepted for Summer Listing in Canada

Xebra Brands Ltd. announced that its Vicious Citrous cannabis infused lemonade, has been accepted by the Ontario Cannabis Store (OCS), for listing and sale in the Province of Ontario, Canada. Vicious Citrus Lemonade combines 10mg of THC with 2mg of CBN (Cannabinol). Vicious Citrus is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America.

At the following link an article on CBN published by MJBizDaily:

Marketing of Xebra’s Vicious Citrous Lemonade can now begin in Ontario, where some 1,143 retail cannabis store licences have been issued, making it by far the most lucrative cannabis market in Canada. Commercial production is scheduled for June 20th, and product is expected to be available on store shelves in Ontario, and in other provinces this coming summer. Xebra has engaged a cannabis sales & marketing agency to introduce Vicious Citrus Lemonade to Canadian cannabis retailers.

In addition, Vicious Citrus Lemonade is believed to be the one and only cannabis product in Canada that utilizes emulsion IP that has undergone Phase I human clinical trials. The trial was carried-out with the approval of Health Canada. Xebra believes that as the cannabis industry develops, that consumers will demand better and safer products, and that claims about characteristics such as absorption, homogeneity, bioavailability, and shelf-life will be more closely scrutinized by regulators, such as the U.S. FDA, and Health Canada.

Other related developments from around the markets include:

Aurora Cannabis announced that the Company has reached an agreement to acquire all of the issued and outstanding shares of TerraFarma Inc. (parent company of Thrive Cannabis). The Transaction is based upon aggregate consideration of $38 million payable in cash and Aurora common shares, plus two earnout amounts payable in Aurora Shares or cash (at the election of Aurora), if applicable, based on Thrive achieving certain revenue targets within two years of closing of the Transaction. The Transaction is expected to strategically strengthen Aurora's position in the Canadian market by placing the Thrive team in charge of Aurora's Canadian recreational portfolio, advancing the shift in focus to innovative premium products including dried flower, pre-rolls, vapour products, and concentrates. The Transaction is expected to close, subject to customary closing conditions, in Aurora's fiscal Q4 2022. It is anticipated that the Transaction will provide immediate positive Adjusted EBITDA to Aurora, and support the Company's path to Adjusted EBITDA profitability in the first half of fiscal 2023.

Canopy Growth, a world-leading diversified cannabis, hemp, and cannabis device company, is unveiling its 7ACRES Know the Grow content series, providing Canadians with an inside look at the talent, genetics and grow techniques behind the brand and flower portfolio. The ten-video series is broken into three chapters: the 7ACRES Kincardine Facility, Growing Techniques, and 7ACRES Craft Collective + Future Vision, with each episode diving into a different element of production. The series launched in mid-February and releases a new episode weekly via the blog, The Stash, as well as on the 7ACRES Instagram channel, @7acresmj.

Tilray Inc. reported financial results for the third fiscal quarter ended February 28, 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, stated, “Our third quarter results reflect progress and momentum across all of our key business segments and geographies, setting the stage to achieve our target for $4B in revenue by the end of fiscal 2024. Tilray Medical – which now operates under a cohesive strategy and mission – has a near 20% share in Germany, providing clear benefits in its own right as well as a first-mover advantage that we will leverage as Germany and the EU move towards broader adult-use and medical use legalization. In Canada, we maintained our leading market share position amid intense competition – and believe that our strong capital position, operational excellence and pricing and marketing adjustments will work in concert to help ensure we reclaim share in the coming quarters. This effort will gain further support from the fundamental appeal of our brands and product innovation which, as stores continue re-opening, will resonate powerfully with consumers. In the U.S., our SweetWater Brewing, Breckenridge Distillery, and Manitoba Harvest businesses are profitable, growing and emerging as nationwide, iconic brands with loyal followings that will be home to THC-based products upon U.S. federal legalization.”

OrganiGram Holdings, a leading licensed producer of cannabis, announced it will report earnings results for its second quarter 2022 ended February 28, 2022 on Tuesday, April 12, 2022 before market open.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Xebra Brands has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Xebra Brands. Click here for disclaimer.

Contact Information:
[email protected]